Diabetic retinopathy (DR) is a microvascular complication of diabetes and is a significant cause of visual impairment and blindness among patients with diabetes. More than 60% of patients with type 2 diabetes are estimated to eventually develop retinopathy ([@B1],[@B2]). The development of DR is broadly classified into nonproliferative and proliferative stages ([@B3]). The nonproliferative stage is characterized by the formation of microaneurysms caused by capillary nonperfusion or abnormal permeability ([@B3]). The advanced proliferative stage develops when retinal ischemia occurs, stimulating the growth of new blood vessels (namely, neovascularization) ([@B3]). The hemorrhage of these fragile blood vessels leads to blood accumulation in the vitreous cavity, potentially resulting in visual impairment ([@B3]). Currently, effective therapeutic interventions remain limited and are based around laser photocoagulation.

The existing, multistage classification of DR development has prompted the wide use of categorical data analysis strategies in clinical studies. Commonly, cross-sectional studies use DR case and control samples in logistic regression analysis or contingency tables for modeling population risk factor effects ([@B4]--[@B7]). Other studies have used the longitudinal nature of DR progression in proportional hazard models ([@B8],[@B9]). To date, however, only one study ([@B10]) has included intermediate states from longitudinal, multistate DR data in the analysis, an approach that provides an increased ability to decipher the stage-wise development of retinopathy compared with a simple survival analysis. In the Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) database, we have ongoing, longitudinal collection of DR clinical outcome from 1990 for Tayside patients with diabetes, and additionally we have access to all biochemistry measurements for these patients. These rich data resources enable us to investigate changes in patients' retinal status over the duration of their diabetes. A multistate Markov model was developed to analyze panel data of a complex, multistaged disease process in continuous time ([@B11]). This longitudinal analysis approach has recently been applied in a wide range of medical fields, including hepatic cancer ([@B12]), diabetes complications ([@B10],[@B13]), breast cancer screening ([@B14]), and liver cirrhosis ([@B15]). The early study ([@B10]) on DR using the multistate Markov approach was not able to assess the clinical effects of relevant risk factors on DR state transitions, possibly owing to insufficient computational power back in the mid-1990s. In this study, we have used the GoDARTS database to incorporate longitudinal measures of multiple risk factors and assess their role in the specific developmental stages of DR.

RESEARCH DESIGN AND METHODS {#s1}
===========================

Description of data {#s2}
-------------------

We performed a prospective cohort study of DR in Tayside, Scotland. Diabetic patients' ophthalmology records were ascertained from the Scottish Care Information Diabetes Collaboration (SCIDC), a Scotland-wide computerized diabetes register. Retinal screening has been undertaken in Tayside since 1990, initially using Polaroid images, with a progression to digital imaging in 2000. The Tayside DR screening protocol has previously been described ([@B16]). In brief, patients undergo screening for diabetic eye disease from diagnosis. Patients' retinopathy stages are determined from grading of single-field 45-degree retinal photographs where staged mydriasis is given. Retinal screening was previously shown to have a sensitivity of \>80% ([@B17],[@B18]) and since 2006 has been adopted as a national screening program in Scotland ([@B19]). The ophthalmology data include DR stages and dates. The retinal events of interest are on a scale from no retinopathy, mild background DR (BDR), observable BDR to severe nonproliferative/proliferative DR (non-PDR/PDR), and diagnostic criteria are described in [Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2392/-/DC1). All retinal events were separately recorded for both eyes. We observed that the numbers of DR events and the distributions of follow-up time collected for both eyes were comparable, and to preclude the artifacts reflected as observed remission and recurrence of the final, stable phase of DR, produced from compounding longitudinal data from both eyes, we collated and analyzed retinopathy data from the same eye.

The ophthalmology data used in this study were from the complete calendar years 1990--2011. GoDARTS is a study of patients with a diagnosis of type 2 diabetes, but we further reduced the chance of including misclassified type 1 diabetes patients by only considering subjects who were diagnoses with diabetes at 35 years of age or older. The cohort included patients who had at least two longitudinal retinal records. The primary start point for this study obtained from this dataset was the first retinal record indicative of no retinopathy within 1 year from the date of diabetes diagnosis. Patients were followed until the onset of severe non-PDR/PDR, date of death, or 16 years' duration of diabetes. Intermediate retinopathy observations were included in this study.

Additional independent datasets (e.g., demography and regional biochemistry database) were integrated through electronic record linkage ([@B20]). Population risk factors extracted were sex, smoking status (ever smoked against never smoked), and longitudinal records of age, BMI, total cholesterol, serum creatinine, diastolic blood pressure (DBP), HbA~1c~, HDL cholesterol (HDL-c), systolic blood pressure (SBP) and triglycerides. Non-HDL-c was estimated from total cholesterol and HDL-c measurements recorded on an identical date. As LDL cholesterol (LDL-c) measurements were often missing, throughout this study non-HDL-c was considered a valid surrogate for LDL-c, which was in concordance with a prior estimate of Pearson correlation coefficient (0.987) that we attained using weighted mean non-HDL-c and LDL-c in the overall GoDARTS sample (16,928 subjects). Time-variant covariates were matched to a retinal event that occurred at the closest time point. Covariates measured on a quantitative scale were standardized by sample mean and SD. In this study, we only included patients with the complete set of covariate data.

Multistate model {#s3}
----------------

The discrete, nonoverlapping stages of DR were translated into distinctive states in the multistate model. The effect of explanatory variables on DR development is modeled in an adapted form of proportional hazard model ([@B10]) ([Supplementary Note](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2392/-/DC1)). Patients\' diabetic duration at retinal examination was considered in the model. Between follow-up visits, patients\' DR development is usually unmonitored, and the exact time of transition from one state to the other is unknown. Thus, we specified a relevant sampling scheme to accommodate an intermittently observed disease process.

Model fitting and comparisons {#s4}
-----------------------------

DR data were analyzed in R (version 2.14.2) software environment, using the "msm" package (version 1.1.1). We postulated two baseline multistate models, which together aimed to decipher the process underlying the development of DR from the observed retinal event data by modeling distinct putative transition paths between states. In the first model, DR development is modeled as one-way progression ([Fig. 1*A*](#F1){ref-type="fig"}), and misclassification was allowed to occur between adjacent states except for the absorbing state ([Supplementary Note](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2392/-/DC1)). The second model is specified by a two-way transition intensity matrix and an identical misclassification probability matrix ([Fig. 1*B*](#F1){ref-type="fig"} and [Supplementary Note](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2392/-/DC1)). The best-fitted model was selected from likelihood ratio (LR) tests and Akaike information criterion (AIC) statistic. This model was then used for assessing covariate effects. Covariate model selection procedures also used LR and AIC measures. The study complies with the Declaration of Helsinki.

![*A*: A base multistate Markov model describes one-way transition of four states of DR. *B*: A second base model describes two-way transition of four states of DR. The process of entering the final absorbing state is irreversible. Rates of transition (or transition intensities) are specified as *q*~ij~, where transition occurs from the current state*i* to the future state *j*.](3979fig1){#F1}

RESULTS {#s5}
=======

Characteristics of the study sample {#s6}
-----------------------------------

Overall, 49,959 retinal measurements were studied in 4,758 diabetes patients ([Supplementary Table 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2392/-/DC1)). At the end of this study, 100 patients developed severe non-PDR/PDR ([Supplementary Table 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2392/-/DC1)). The full raw data on numbers and prevalence of retinal events, state transitions, and additionally, the statistically estimated misclassification probabilities are shown in [Supplementary Tables 2--7 and 10](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2392/-/DC1), [Fig. 2](#F2){ref-type="fig"}, and [Supplementary Fig. 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2392/-/DC1).

![Prevalence of DR in the GoDARTS panel data by duration of diabetes. This shows the retinopathy state as a percentage of the sample, recorded at each year of duration of diabetes from 1 to 16 years of diabetes duration.](3979fig2){#F2}

Baseline model without risk factor adjustment {#s7}
---------------------------------------------

Initial unadjusted modeling demonstrated the better fit of the two-way transition model (one-way transition model AIC 32,042.2, two-way transition model AIC 31,574.2; *P* \< 0.0001). A comparison between the observed and model-predicted prevalence indicated a close fit of the model to the DR data and thus supported the internal validity of the model ([Supplementary Fig. 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2392/-/DC1)).

This model indicated that the rates of remission from mild BDR to a DR-free state and from observable BDR to mild BDR were significantly faster than the rates of progression (2.0 times faster and 4.2 times faster, respectively), with the remission from observable to mild being almost double the rate of that observed for mild to no retinopathy ([Supplementary Table 8](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2392/-/DC1)). The expected total length of time for DR-free, mild BDR, observable BDR, and severe non-PDR/PDR states were 12.6 years (95% CI 12.41--12.83), 2.91 years (95% CI 2.70--3.11), 0.37 years (95% CI 0.27--0.48), and 0.11 years (95% CI 0.06--0.19), respectively. For the maximum follow-up time (16 years), the estimated transition matrix showed 26, 4.3, and 2% probabilities that a patient free of DR will progress to mild background, observable, and severe non-PDR/PDR, respectively ([Supplementary Table 9](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2392/-/DC1)).

Assessment of traditional risk factors {#s8}
--------------------------------------

We standardized values of BMI, cholesterol, creatinine, DBP, HbA~1c~, HDL-c, SBP, triglycerides, and non-HDL-c ([Supplementary Table 13](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2392/-/DC1)). As we have the full longitudinal medical record of each patient, we adjusted each specific retinal event using risk factor data that were measured as close to that event as available. We found that BMI, DBP, HbA~1c~, and SBP provided generally very close measures for each retinal assessment, probably due to their measure by diabetes specialists ([Supplementary Table 13](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2392/-/DC1)). However, measures of vascular risk such as total cholesterol, serum creatinine, HDL-c, triglycerides, and non-HDL-c were measured more distally to the retinal screening events ([Supplementary Table 13](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2392/-/DC1)).

In a univariate analyses, there was a significant effect on progression rates for age of diagnosis, age, cholesterol, DBP, HbA~1c~, SBP, triglycerides, and non-HDL-c, even after Bonferroni correction (threshold 0.0038) ([Table 1](#T1){ref-type="table"}). In contrast, there was no significant effect of BMI, serum creatinine, HDL-c, sex, or smoking status ([Table 1](#T1){ref-type="table"} and [Supplementary Table 14](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2392/-/DC1)). We then examined the effects of the risk factors on the individual transitions between disease states. An increase in HbA~1c~ level by 1 SD (15.83 mmol/mol, 1.4%) had a 42% increased risk of progression from no retinopathy state to mild BDR, a 32% increased risk of progression from mild BDR to observable BDR, and a 123% increased risk in progression from observable BDR to severe non**-**PDR/PDR ([Table 2](#T2){ref-type="table"}). Conversely, a reduction in the HbA~1c~ level by 1 SD was associated with a 24% increased possibility of recovering from mild BDR to the retinopathy-free state ([Table 2](#T2){ref-type="table"}), but the HbA~1c~ level was unrelated to the regression from observable BDR to mild BDR in this cohort. A raised level of DBP by 1 SD (10.41 mmHg) elevated the risk for developing observable BDR from the mild BDR by 87% ([Table 2](#T2){ref-type="table"}). SBP was also a significant risk factor for progression to mild BDR from the initial retinopathy-free state ([Table 2](#T2){ref-type="table"}), and the reduction in SBP by 1 SD (17.28 mmHg) was associated with a 20% increased chance of regression back to the retinopathy-free state ([Table 2](#T2){ref-type="table"}). The risk effect of cholesterol and non-HDL-c on the progression from mild BDR to observable BDR reached statistical significance in the univariate models ([Table 2](#T2){ref-type="table"}) but was insignificant after adjustment in the multivariate model ([Table 2](#T2){ref-type="table"}). In the multivariate analysis, at the 5% significance level, triglyceride values influenced the transition from the retinopathy-free state to mild BDR ([Table 2](#T2){ref-type="table"}), which, however was statistically insignificant in the univariate assessment ([Table 2](#T2){ref-type="table"}).

###### 

LR tests of single-covariable model against the two-way transition model (base model AIC 31,574.2)

![](3979tbl1)

###### 

HR (95% CI) for DR progression (state 1--2, 2--3, and 3--4) and regression (state 2--1, 3--2)

![](3979tbl2)

CONCLUSIONS {#s9}
===========

Our analysis has demonstrated that in the development of DR, the initial, asymptomatic phase was stable, followed by transient mid-stages, and that substantial rates of disease regression could be observed. The risk of DR progression from the retinopathy-free state to mild BDR, from mild BDR to observable BDR, and from observable BDR to severe non-PDR/PDR was strongly positively associated with glycemic exposure. We also found a significant risk effect of DBP on the progression of mild BDR to observable BDR and of SBP on the state transition from the retinopathy-free state to mild BDR. There was no evidence in this study that the risk effects for DR state transitions were influenced by sex, smoking status, BMI, serum creatinine, or HDL-c. We did not find the evidence for independent risk effects of cholesterol, triglycerides, and non-HDL-c on DR state transitions with the adjustment for blood pressure and glycemic control. This study provides the first evidence showing that better HbA~1c~ and SBP are strongly correlated with the regression from mild BDR back to the retinopathy-free state.

One of the strengths of this study is the 15-fold greater overall sample size compared with an earlier study on DR using an identical approach and a substantially extended follow-up time. A potential limitation in this longitudinal study of historical events remains the paucity of follow-up data on the study subjects that were recruited more recently. Also, halfway through, the follow-up screening was switched from Polaroid films to digital images, although a similar grading category was followed.

In this study, our data yielded an important novel estimation about the time spent in each state in this cohort. To date, most longitudinal studies on DR development have been directed at estimating incidence and/or progression rate in a study sample, and few have examined the average length of time spent in each stage of DR. In the late 1980s, the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) reported that 0.4% of patients with diabetes diagnosed at ≥30 years of age and without retinopathy at the first retinal examination progressed to PDR within 4 years ([@B21]). The UK Prospective Diabetes Study (UKPDS) identified that 0.2% of 2,316 type 2 diabetic patients with no retinopathy at baseline required photocoagulation treatments at 3 years, 1.1% at 6 years, and 2.6% at 9 years ([@B22],[@B23]). A recent study on 16,444 patients with type 2 diabetes without retinopathy at the first retinal examination found that the cumulative incidence of non-PDR, severe non-PDR, and PDR was 36, 4, and 0.68%, respectively, after 5 years follow-up, and after 10 years follow-up, these estimates rose to 66, 16, and 1.5%, respectively ([@B24]). These findings broadly support the estimated total length of time in the retinopathy-free state reported in this study.

Extensive evidence from published randomized clinical trials ([@B25]--[@B27]) and prospective ([@B28]--[@B34]) and retrospective ([@B35]) studies support our findings on HbA~1c~ as an important risk factor for DR progression ([Table 2](#T2){ref-type="table"}). The Diabetes Control and Complications Trial (DCCT) ([@B27]) reported a hazard rate of 1.63 (*P* \< 0.001) for the risk effect of 1 SD of HbA~1c~ in type 1 diabetic patients. UKPDS ([@B26]) has found per 1-SD increase in the HbA~1c~ variable a hazard rate of 1.48 (95% CI 1.40--1.61) and 1.96 (95% CI 1.79--2.16), respectively, for microvascular complications in patients with type 2 diabetes. These results broadly support the hazard ratios (HRs) we found in this study for HbA~1c~ on DR. Additionally, we demonstrate that lower HbA~1c~ is associated with regression of retinopathy from mild BDR to no DR. However, once a more severe retinopathy state, e.g., observable BDR is reached, the protective effect associated with lowering HbA~1c~ is not observed, suggesting that good glycemic control only facilitates DR remission at an early stage.

Previous studies have shown mixed results on the association between blood pressure and DR. The UKPDS ([@B23]) demonstrated that the incidence of retinopathy was associated with SBP values in top versus bottom tertiles and that lowering blood pressure resulted in a marked reduction in development or progression of DR. In one of the WESDR reports ([@B29]), in which a prospective cohort of type 1 diabetic patients was followed up for 14 years, the baseline DBP variable was a significant predictor of progression to PDR. A study in the late-1980s ([@B36]) showed no association of SBP and DBP variables in the highest and lowest quartiles with the incidence or the progression of retinopathy in type 2 diabetic patients. In contrast, it was shown in the same study that in type 1 diabetic patients, SBP and DBP were correlated with the progression of retinopathy. Our study firmly supports a role for blood pressure in DR progression in individuals with type 2 diabetes.

In this study, we have applied an innovative approach for the analysis of population-based longitudinal retinopathy cohort data. Our findings delineated state-by-state transitions underlying DR development, and our assessment of population risk factors influencing progressive and regressive state transitions yielded the evidence for the role of blood pressure and glycemic control in DR development. Furthermore, the analytical approach used in this study holds the potential to be extended for investigating the additional independent effect from antidiabetes oral agents on the course of DR or the interaction between antidiabetes medications with HbA~1c~ on the development of DR. These lines of interest on the front of pharmacoepidemiology may deserve a separate, thorough investigation, with additional input from population prescribing datasets. However, we have the confidence that the strategy we applied here will become the cornerstone for increasingly more clinical studies.

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2392/-/DC1>.
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